Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis
复制标题
DOI：
10.1002/art.21023
复制
发表时间：
2005-05-01
影响因子：
--
通讯作者：
Ikeda, Y
中科院分区：
文献类型：
--
作者：
Sato, S;Hirakata, M;Ikeda, Y
客观的。鉴定针对皮肌炎 (DM) 的新型自身抗体，特别是针对临床无肌病 DM (C-ADM) 的特异性抗体。方法。通过免疫沉淀法分析了来自各种结缔组织疾病 (CTD) 或特发性肺纤维化 (IPF) 患者的 298 份血清样本中的自身抗体。通过免疫印迹和间接免疫荧光（IF）进一步检查血清的抗原特异性。确定与感兴趣的抗体相关的疾病特异性和临床特征。结果。通过免疫沉淀和免疫印迹，8份血清识别出与140 kd相似的多肽（CADM-140自身抗原）。在细胞质中检测到免疫反应性，间接 IF 显示颗粒状或网状图案。在 42 名 DM 患者中，有 8 名检测到了抗 CADM-140 抗体，但在其他 CTD 或 IPF 患者中未检测到。有趣的是，所有 8 名具有抗 CADM-140 抗体的患者均患有 C-ADM。在 42 名 DM 患者中，与不具有抗 CADM-140 自身抗体的患者相比，具有抗 CADM-140 自身抗体的患者的间质性肺疾病 (ILD) 进展速度明显更快（50% vs 6%；P = 0.008）。结论。这些结果表明抗CADM-140自身抗体的存在可能是C-ADM的新标志物。应进一步关注具有抗 CADM-140 自身抗体的患者中快速进展 ILD 的检测。
Objective. To identify novel autoantibodies specific for dermatomyositis (DM), especially those specific for clinically amyopathic DM (C-ADM).Methods. Autoantibodies were analyzed by immunoprecipitation in 298 serum samples from patients with various connective tissue diseases (CTDs) or idiopathic pulmonary fibrosis (IPF). Antigen specificity of the sera was further examined by immunoblotting and indirect immunofluorescence (IF). The disease specificity and clinical features associated with the antibody of interest were determined.Results. Eight sera recognized a polypeptide of similar to 140 kd (CADM-140 autoantigen) by immunoprecipitation and immunoblotting. Immunoreactivity was detected in the cytoplasm, and indirect IF revealed a granular or reticular pattern. Anti-CADM-140 antibodies were detected in 8 of 42 patients with DM, but not in patients with other CTDs or IPF. Interestingly, all 8 patients with anti-CADM-140 antibodies had C-ADM. Among 42 patients with DM, those with anti-CADM-140 autoantibodies had significantly more rapidly progressive interstitial lung disease (ILD) when compared with patients without anti-CADM-140 autoantibodies (50% versus 6%; P = 0.008).Conclusion. These results indicate that the presence of anti-CADM-140 autoantibodies may be a novel marker for C-ADM. Further attention should be directed to the detection of rapidly progressive ILD in those patients with anti-CADM-140 autoantibodies.